Prospective Randomized Trial of Emtricitabine versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus-Infected Patients

Journal of Infectious Diseases

Volumn 188, Issue 11, 2003, Pages 1652-1658

  Rousseau, Franck S ^a   Wakeford, Charles ^a   Mommeja Marin, Herve ^a   Sanne, Ian ^b   Moxham, Cary ^a   Harris, Jeanette ^a   Hulett, Laura ^a   Wang, Laurene H ^a   Quinn, Joseph B ^a   Barry, David W ^a  

^a Triangle Pharmaceuticals   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE;

ADULT; ANTIVIRAL ACTIVITY; APPETITE DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; LAMIVUDINE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0347918826     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379667     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. New data show continued decline in AIDS deaths. Available at: http://www.cdc.gov/od/oc/media/ pressrel/r990831/htm.
2. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and long-term efficacy. Lancet 2001; 358:1760-5.
3. Frost SDW, Nijhuis M, Schuurman R, Boucher CAB, Brown AJL. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000; 74:6262-8.
4. Schinazi RF, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2- (hydromethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36:2423-31.
5. Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001; 48:507-13.
6. Mathez D, Schinazi RF, Liotta DC, Leibowitch J. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993; 37:2206-11.
7. Schinazi R, Chu C, Peck A, et al. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (bch-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 1992; 36:672-6.
8. Schinazi, RF, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[f2- (hydroxymethyl)-1],3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36:2423-31.
9. Painter G, Rimsky LT, Furman P, Liotta D, Schinazi R, Quinn J. Preclinical and clinical development of the anti-HIV, anti HBV oxathiolane nucleoside analog emtricitabine. In: Schinazi R, Rice C, Sommadissi JP, eds. Frontiers in viral hepatitis. London: Elsevier Science, 2003:453-86.
10. Mathez D, Schinazi RF, Liotta DC, Leibowitch J. Infectious amplificatin of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993; 37:2206-11.
11. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antivir Ther 2001; 6:83-8.
12. Gosselin G, Schinazi RF, Sommadossi JP, et al. Anti-human immunodeficiency virus activities of the β-1 enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother 1994; 38:1292-7.
13. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003; 32:255-8.
14. Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 1999; 13:1511-7.
15. Sanne I, van der Horst C, Shaw A. Two randomized, controlled equivalence trials of emtricitabine (FTC) to lamivudine (3TC) [poster 4432]. In: Program and abstracts of the XIV World AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:94.
16. Sanne I, Saag M, Shaw A, et al. Efficacy of emtricitabine (FTC) in HIV-infected patients with high pre-treatment viral load [abstract 546]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris). Stockholm: International AIDS Society, 2003:159.
17. Wang LH, Begley J, Feng JY, Quinn J, Rousseau F. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing [poster 4546]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:98.